Table 2.
Associations of neutropenia with acute respiratory distress syndrome risk, acute kidney injury risk, and mortality
| Standardized risk, % (95 % CI)a | ||||||
|---|---|---|---|---|---|---|
| Outcomes | Neutropenic | Non-neutropenic | Unadjusted RRb (95 % CI) | p | Adjusted RRb (95 % CI) | p |
| ARDSc | 36 % (27, 44 %) | 40 % (36, 43 %) | 1.09 (0.85, 1.40) | 0.51 | 0.90 (0.70, 1.17) | 0.42 |
| AKId | 54 % (44, 64 %) | 42 % (38, 46 %) | 1.39 (1.15, 1.69) | 0.002 | 1.28 (1.04, 1.57) | 0.03 |
| 30-day mortalitye | 44 % (36, 53 %) | 42 % (39, 46 %) | 1.29 (1.05, 1.58) | 0.03 | 1.05 (0.85, 1.31) | 0.65 |
| 60-day mortalitye | 52 % (43, 61 %) | 46 % (43, 49 %) | 1.34 (1.12, 1.60) | 0.004 | 1.13 (0.93, 1.37) | 0.23 |
CI confidence interval, RR relative risk, ARDS acute respiratory distress syndrome, AKI acute kidney injury, APACHE acute physiology and chronic health evaluation
aStandardized risks and 95 % confidence intervals by neutropenic status were determined using post-estimation marginal analyses of adjusted multivariable logistic regression models
bRR and 95 % confidence intervals were estimated using post-estimation marginal analyses of logistic regression models
cFinal ARDS logistic regression models were adjusted for age, sex, race, source of sepsis, admission source, history of chronic renal insufficiency, history of chronic liver disease, and APACHE III without immunocompromising conditions, white blood cell, and arterial blood gas components
dFinal AKI logistic regression models were adjusted for age, sex, race, source of sepsis, admission source, history of diabetes mellitus, history of congestive heart failure, history of chronic renal insufficiency, history of chronic liver disease, and APACHE III without immunocompromising conditions, white blood cell, and renal components
eFinal mortality logistic regression models were adjusted for age, sex, race, source of sepsis, admission source, history of diabetes mellitus, history of congestive heart failure, history of chronic renal insufficiency, history of chronic liver disease, and APACHE III without immunocompromising conditions and white blood cell components